A NEW SIMPLE, PERSONALIZED, AND QUANTITATIVE EMPIRICAL METHOD FOR DETERMINING I ACTIVITY IN TREATING GRAVES' DISEASE

Overview

Journal Acta Endocrinol (Buchar)

Specialty Endocrinology

Date 2020 Dec 28

PMID 33363655

Citations 1

Authors

F Xu

A Gu

Y Ma

Affiliations

Soon will be listed here.

Abstract

Context: The I activity for treating Graves' disease (GD) is usually determined based on physician's experience.

Objective: This study aimed to design an empirical method that was not only personalized and quantitative, but also simple, convenient, and easy to grasp.

Subjects And Methods: The study population comprised patients with GD, selected between May 2013 and May 2016, who received I therapy in the Outpatient Department of Shanghai Ninth People's Hospital. The first-visit patients of physician 1 were placed in the traditional group: the activity of I (mCi) was calculated using the routine formula: [empirical activity (0.07-0.12 mCi/g) × thyroid mass]/[24-h thyroid I uptake]. The first-visit patients of physician 2 were placed in the personalized group. The activity of I (mCi) was calculated in two steps. First, the initial activity was calculated: 0.1 mCi/g × thyroid mass (g), and then a personalized and quantitative calibration table of I activity was used to obtain a final I activity. The cure rate with a single activity of I was recorded 1 year later.

Results: The traditional and personalized groups included 241 and 282 patients, respectively. Interestingly, the personalized group achieved a higher cure rate [86.5% (244/282) 73.4% (177/241), P = 0.000] with a relatively higher I activity for the first treatment [8.7 (7, 3.5-30) mCi 6.7(6, 2.5-30) mCi, P = 0.000] compared with the traditional group, while the incidence rate of permanent hypothyroidism was not significantly different between the two groups (P = 0.175).

Conclusion: The empirical method designed in this study was reliable.

Citing Articles

Ultrasound combined with Ki-67 to construct the prognostic model for radioactive iodine therapy outcomes in Graves' disease patients.

Wang Y, Hong L, Yang C, Lv G, Wang K, Huang X Endocr Connect. 2023; 13(2).

PMID: 38108761 PMC: 10831585. DOI: 10.1530/EC-23-0429.

References

Iagaru A, McDougall I . Treatment of thyrotoxicosis. J Nucl Med. 2007; 48(3):379-89. View

Kalinyak J, McDougall I . How should the dose of iodine-131 be determined in the treatment of Graves' hyperthyroidism?. J Clin Endocrinol Metab. 2003; 88(3):975-7. DOI: 10.1210/jc.2002-021801. View

Hyer S, Pratt B, Gray M, Chittenden S, Du Y, Harmer C . Dosimetry-based treatment for Graves' disease. Nucl Med Commun. 2018; 39(6):486-492. PMC: 5965923. DOI: 10.1097/MNM.0000000000000826. View

Zantut-Wittmann D, Ramos C, Santos A, Lima M, Panzan A, Facuri F . High pre-therapy [99mTc]pertechnetate thyroid uptake, thyroid size and thyrostatic drugs: predictive factors of failure in [131I]iodide therapy in Graves' disease. Nucl Med Commun. 2005; 26(11):957-63. DOI: 10.1097/01.mnm.0000183795.59097.42. View

Donovan P, McLeod D, Little R, Gordon L . Cost-utility analysis comparing radioactive iodine, anti-thyroid drugs and total thyroidectomy for primary treatment of Graves' disease. Eur J Endocrinol. 2016; 175(6):595-603. DOI: 10.1530/EJE-16-0527. View

Solomon B, Glinoer D, Lagasse R, Wartofsky L . Current trends in the management of Graves' disease. J Clin Endocrinol Metab. 1990; 70(6):1518-24. DOI: 10.1210/jcem-70-6-1518. View

WATSON A, Brownlie B, Frampton C, Turner J, Rogers T . Outcome following standardized 185 MBq dose 131I therapy for Graves' disease. Clin Endocrinol (Oxf). 1988; 28(5):487-96. DOI: 10.1111/j.1365-2265.1988.tb03683.x. View

Franklyn J, Daykin J, Drolc Z, Farmer M, Sheppard M . Long-term follow-up of treatment of thyrotoxicosis by three different methods. Clin Endocrinol (Oxf). 1991; 34(1):71-6. DOI: 10.1111/j.1365-2265.1991.tb01738.x. View

Schiavo M, Bagnara M, Calamia I, Bossert I, Ceresola E, Massaro F . A study of the efficacy of radioiodine therapy with individualized dosimetry in Graves' disease: need to retarget the radiation committed dose to the thyroid. J Endocrinol Invest. 2010; 34(3):201-5. DOI: 10.1007/BF03347067. View

10.

Bonnema S, Bennedbaek F, Veje A, Marving J, Hegedus L . Propylthiouracil before 131I therapy of hyperthyroid diseases: effect on cure rate evaluated by a randomized clinical trial. J Clin Endocrinol Metab. 2004; 89(9):4439-44. DOI: 10.1210/jc.2004-0247. View

11.

Vanderpump M, Tunbridge W, French J, Appleton D, Bates D, Clark F . The incidence of thyroid disorders in the community: a twenty-year follow-up of the Whickham Survey. Clin Endocrinol (Oxf). 1995; 43(1):55-68. DOI: 10.1111/j.1365-2265.1995.tb01894.x. View

12.

Moura-Neto A, Mosci C, Santos A, Amorim B, de Lima M, Etchebehere E . Predictive factors of failure in a fixed 15 mCi 131I-iodide therapy for Graves' disease. Clin Nucl Med. 2012; 37(6):550-4. DOI: 10.1097/RLU.0b013e31824851d1. View

13.

Leslie W, Ward L, Salamon E, Ludwig S, Rowe R, Cowden E . A randomized comparison of radioiodine doses in Graves' hyperthyroidism. J Clin Endocrinol Metab. 2003; 88(3):978-83. DOI: 10.1210/jc.2002-020805. View

14.

Allahabadia A, Daykin J, Holder R, Sheppard M, Gough S, Franklyn J . Age and gender predict the outcome of treatment for Graves' hyperthyroidism. J Clin Endocrinol Metab. 2000; 85(3):1038-42. DOI: 10.1210/jcem.85.3.6430. View

15.

Metso S, Jaatinen P, Huhtala H, Luukkaala T, Oksala H, Salmi J . Long-term follow-up study of radioiodine treatment of hyperthyroidism. Clin Endocrinol (Oxf). 2004; 61(5):641-8. DOI: 10.1111/j.1365-2265.2004.02152.x. View

16.

Sabri O, Zimny M, Schulz G, Schreckenberger M, Reinartz P, Willmes K . Success rate of radioiodine therapy in Graves' disease: the influence of thyrostatic medication. J Clin Endocrinol Metab. 1999; 84(4):1229-33. DOI: 10.1210/jcem.84.4.5588. View

17.

NORDYKE R, GILBERT Jr F . Optimal iodine-131 dose for eliminating hyperthyroidism in Graves' disease. J Nucl Med. 1991; 32(3):411-6. View

18.

Bahn R, Burch H, Cooper D, Garber J, Greenlee M, Klein I . Hyperthyroidism and other causes of thyrotoxicosis: management guidelines of the American Thyroid Association and American Association of Clinical Endocrinologists. Endocr Pract. 2011; 17(3):456-520. DOI: 10.4158/ep.17.3.456. View

19.

Alexander E, Larsen P . High dose of (131)I therapy for the treatment of hyperthyroidism caused by Graves' disease. J Clin Endocrinol Metab. 2002; 87(3):1073-7. DOI: 10.1210/jcem.87.3.8333. View

20.

Gomez-Arnaiz N, ANDIA E, Guma A, Abos R, Soler J, Gomez J . Ultrasonographic thyroid volume as a reliable prognostic index of radioiodine-131 treatment outcome in Graves' disease hyperthyroidism. Horm Metab Res. 2003; 35(8):492-7. DOI: 10.1055/s-2003-41807. View